HDAC6 Deacetylates HMGN2 to Regulate Stat5a Activity and Breast Cancer Growth

Area of Science:

• Molecular biology
• Cancer research
• Epigenetics

Background:

• Signal transducer and activator of transcription 5a (Stat5a) is crucial for cancer cell proliferation, differentiation, and survival.
• Stat5a activity is implicated in breast cancer pathogenesis, yet no direct therapies targeting it are approved.
• The coactivator and chromatin-remodeling protein HMGN2 plays a role in Stat5a-mediated transcription.

Purpose of the Study:

• To investigate the role of HMGN2 deacetylation by HDAC6 in Stat5a-mediated transcription and breast cancer growth.
• To evaluate the therapeutic potential of HDAC6 inhibition in breast cancer treatment.

Main Methods:

• In vitro and in vivo studies involving HDAC6 inhibition.
• Analysis of HMGN2 acetylation status in normal and tumor breast tissues.
• Assessment of Stat5a-mediated signaling pathways.

Main Results:

• Deacetylation of HMGN2 at lysine residue K2 by HDAC6 promotes Stat5a-mediated transcription and breast cancer growth.
• HDAC6 inhibition leads to increased HMGN2 acetylation, reduced Stat5a signaling, and inhibited breast cancer growth.
• HMGN2 is deacetylated in primary breast tumors and metastases compared to normal breast tissue.

Conclusions:

• HDAC6 activity promotes Stat5a target gene transcription and breast cancer progression through HMGN2 deacetylation.
• Targeting HMGN2 deacetylation via HDAC6 inhibition represents a promising therapeutic strategy for breast cancer.